Genexine제넥신
095700 · KOSDAQ · ₩095700 · 제넥신
₩2,165▼ ₩85 (3.78%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩4.6B | ₩2.9B | ₩3.9B | ₩16B | ₩38B |
| Cost of sales | ₩5B | ₩4.2B | ₩2.5B | ₩4.6B | ₩5B |
| Gross profit | −₩386M | −₩1.2B | ₩1.3B | ₩11B | ₩33B |
| Operating income | −₩36B | −₩37B | −₩40B | −₩34B | −₩16B |
| Net income | −₩27B | −₩64B | −₩39B | −₩45B | −₩51B |
| Net income to shareholders | −₩27B | −₩64B | −₩39B | −₩45B | −₩51B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩371B | ₩345B | ₩413B | ₩394B | ₩636B |
| Current assets | ₩46B | ₩47B | ₩84B | ₩43B | ₩50B |
| Cash and equivalents | ₩9.2B | ₩1.2B | ₩2.7B | ₩12B | ₩21B |
| Total liabilities | ₩125B | ₩83B | ₩80B | ₩107B | ₩114B |
| Current liabilities | ₩117B | ₩54B | ₩55B | ₩78B | ₩59B |
| Borrowings | ₩108B | ₩76B | ₩67B | ₩84B | ₩52B |
| Total equity | ₩247B | ₩262B | ₩332B | ₩286B | ₩523B |
| Shareholders' equity | ₩247B | ₩262B | ₩332B | ₩286B | ₩523B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩30B | −₩1.6B | −₩36B | −₩41B | −₩9B |
| Capital spending | ₩15B | ₩7.3B | ₩7.1B | ₩27B | ₩52B |
| Free cash flow | −₩44B | −₩8.9B | −₩43B | −₩68B | −₩61B |
Consolidated where available. Amounts in won.
Also known as: Genexine / 제넥신 / 095700 / KRX:095700
Source: KRX statistical information